Intelligyn passed its Stage II QMS audit
This milestone moves them closer to CE marking for their AI tool, aiming to improve ovarian tumour assessment globally.
See the latest news and media coverage for Intelligyn. We track all announcements, press releases, and industry mentions in real time, all in one place.
Artificial intelligence company developing gynecological diagnostic tools
intelligyn.aiLast updated
In short: Intelligyn passed its Stage II QMS audit, advancing toward CE marking for its AI tool for ovarian tumour assessment.
This milestone moves them closer to CE marking for their AI tool, aiming to improve ovarian tumour assessment globally.
She brings extensive life sciences experience from senior roles at AstraZeneca, Amgen, and Shire.
Developed from clinical research at Karolinska Institute, it improves clinicians' ability to characterize ovarian lesions.
The collaboration combines medical expertise, AI tool, and Samsung ultrasound technology.
Track Intelligyn and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.